A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia-Reference-Cited by-同舟云学术

A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia

Published:2015-03 Issue:3 Volume:110 Page:423-431
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Hosonuma Kenichi,Sato Ken,Yamazaki Yuichi,Yanagisawa Masatoshi,Hashizume Hiroaki,Horiguchi Norio,Kakizaki Satoru,Kusano Motoyasu,Yamada Masanobu

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg201520.pdf

Reference31 articles.

1. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.;Shi;Am J Gastroenterol,2006

2. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.;ter Borg;Am J Gastroenterol,2006

3. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.;Corpechot;Gastroenterology,2002

4. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.;Combes;Hepatology,2005

5. A European multicentre study group.;J Hepatol,1993

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary biliary cholangitis;The Lancet;2024-09

2. S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV);Zeitschrift für Gastroenterologie;2024-09

3. PPAR agonists in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;2024-05-14

4. Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice;Alimentary Pharmacology & Therapeutics;2024-05

5. Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?;Hepatology;2024-03-22